AIM ImmunoTech Secures Japanese Patent for Ampligen Checkpoint Combo Therapy Expiring 2039
Japan Patent Office granted AIM ImmunoTech a patent for Ampligen combined with anti-PD-1/PD-L1 antibodies, covering multiple cancer types including pancreatic cancer, valid until December 20, 2039. The company plans to seek Japanese Orphan Drug Designation for Ampligen in pancreatic cancer, complementing existing U.S. and EU designations.
1. Japanese Patent Approval
In March 2026, the Japan Patent Office fully approved AIM’s patent covering Ampligen use with anti-PD-1/PD-L1 antibodies for cancer treatment after a six-month opposition period.
2. Patent Scope and Expiry
The allowed claims encompass Ampligen in combination therapy across multiple cancer types, including pancreatic cancer, and the patent extends to December 20, 2039.
3. Orphan Drug Designation Plans
AIM intends to pursue Orphan Drug Designation in Japan for Ampligen in pancreatic cancer, adding to its existing U.S. and EU designations that offer market exclusivity benefits.
4. Global Intellectual Property Portfolio
AIM also holds a U.S. patent expiring August 9, 2039, and a Netherlands patent expiring December 19, 2039, underscoring its strategy to protect Ampligen combination therapies worldwide.